BiomX, Inc. (PHGE)

NYSEAMERICAN: PHGE · IEX Real-Time Price · USD
0.725
-0.039 (-5.14%)
May 27, 2022 4:00 PM EDT - Market closed
Market Cap22.65M
Revenue (ttm)n/a
Net Income (ttm)-35.99M
Shares Out31.24M
EPS (ttm)-1.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume43,360
Open0.776
Previous Close0.764
Day's Range0.694 - 0.780
52-Week Range0.640 - 6.730
Beta0.59
AnalystsBuy
Price Target10.97 (+1,413.1%)
Earnings DateMay 11, 2022

About PHGE

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinic...

IndustryBiotechnology
Founded2015
Employees103
Stock ExchangeNYSEAMERICAN
Ticker SymbolPHGE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for PHGE stock is "Buy." The 12-month stock price forecast is 10.97, which is an increase of 1,413.10% from the latest price.

Price Target
$10.97
(1,413.10% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BiomX Slashes Its Workforce By 50%, Atopic Dermatitis Program To Be Delayed

BiomX Inc (NYSE: PHGE) announced a corporate restructuring plan to focus its resources and extend the cash runway. The company had $55.7 million in cash, cash equivalents, short-term deposits, and a $15...

4 days ago - Benzinga

BiomX Announces Corporate Restructuring

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...

4 days ago - Business Wire

BiomX Announces Publication in the Journal, Bioinformatics

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...

1 week ago - Business Wire

BiomX Reports First Quarter 2022 Financial Results and Provides Business Update

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...

2 weeks ago - Business Wire

BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis...

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...

3 weeks ago - Business Wire

BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...

3 weeks ago - Business Wire

BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...

1 month ago - Business Wire

BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target s...

2 months ago - Business Wire

BiomX Presenting at Three Upcoming Investor Conferences

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Presenting at Three Upcoming Investor Conferences

3 months ago - Business Wire

BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...

4 months ago - Business Wire

BiomX Presenting at Two Upcoming Conferences in November

Jefferies London Healthcare Conference on November 18 - 19, 2021

6 months ago - GlobeNewsWire

BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update

Announces Strategic Focus on Cystic Fibrosis and Atopic Dermatitis Programs Based on Potential Proof-of-Concept Clinical Data Readouts in 2022

6 months ago - GlobeNewsWire

Down 28.1% in 4 Weeks, Here's Why BiomX Inc. (PHGE) Looks Ripe for a Turnaround

BiomX Inc. (PHGE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

7 months ago - Zacks Investment Research

BiomX's Acne Vulgaris Treatment Fails To Top Vehicle Treatment Cohort

BiomX Inc (NYSE: PHGE) announced results from its Phase 2 study to assess BX001 to improve the appearance of skin in acne-prone subjects.  A statistically significant improvement from baseline was obser...

7 months ago - Benzinga

BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study

12-Week Study of BX001 Meets Safety and Tolerability Endpoints

7 months ago - GlobeNewsWire

BiomX Enters Agreement Granting Maruho Co. A right Of First Offer To License BiomX's Atopic Dermatitis Product Candid...

BiomX Inc. (NYSE: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced today t...

7 months ago - Benzinga

BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and eng...

7 months ago - GlobeNewsWire

BiomX to Present at Upcoming September Investor Conferences

BRANFORD, Conn. and NESS ZIONA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and en...

8 months ago - GlobeNewsWire

BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update

Up to $45 Million Secured from Recent Capital Raises Extends Cash Runway to at Least Mid-2023

9 months ago - GlobeNewsWire

BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021

NESS ZIONA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therap...

9 months ago - GlobeNewsWire

BiomX Inc. Announces $15 Million Registered Direct Offering

NESS ZIONA, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therap...

10 months ago - GlobeNewsWire

BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Vir...

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target s...

11 months ago - Business Wire

BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target s...

11 months ago - Business Wire

BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target s...

1 year ago - Business Wire

BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease

Live webinar to be held on Wednesday, May 26th at 8:00 AM EDT Live webinar to be held on Wednesday, May 26th at 8:00 AM EDT

1 year ago - GlobeNewsWire